Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
CDTX
Stock Latest News
Ratings
Optimistic Buy Rating for Cidara Therapeutics Ahead of Phase 2b Flu Trial Results
10d ago
CDTX
Premium
Ratings
Strong Buy Rating for Cidara Therapeutics: CD388’s Revolutionary Potential in Flu Treatment and Beyond
15d ago
CDTX
Premium
The Fly
Cidara Therapeutics price target raised to $35 from $31 at RBC Capital
22d ago
CDTX
Premium
The Fly
Cidara Therapeutics price target raised to $50 from $35 at Guggenheim
29d ago
CDTX
Premium
Ratings
Promising Developments and Upcoming Data Release Drive Buy Rating for Cidara Therapeutics
30d ago
CDTX
Premium
Company Announcements
Cidara Therapeutics’ CD388 Progress and Challenges Highlighted in Earnings Call
1M ago
CDTX
Premium
The Fly
Cidara Therapeutics price target raised to $35 from $33 at Guggenheim
1M ago
CDTX
Premium
Ratings
Promising Outlook for Cidara Therapeutics: Buy Rating Affirmed Amid Upcoming R&D Insights and Strategic FDA Engagement
1M ago
CDTX
Premium
The Fly
Cidara Therapeutics price target raised to $47 from $46 at Citizens JMP
1M ago
CDTX
Premium
Company Announcements
Cidara Therapeutics Reports Q1 2025 Financial Results
1M ago
CDTX
Premium
The Fly
Cidara Therapeutics reports Q1 EPS ($1.66) vs. ($2.28) last year
1M ago
CDTX
Premium
The Fly
Cidara Therapeutics files $500M mixed securities shelf
1M ago
CDTX
Premium
Pre-Earnings
Cidara Therapeutics Inc. (CDTX) Q1 Earnings Cheat Sheet
1M ago
CDTX
Premium
The Fly
Cidara Therapeutics management to meet virtually with Needham
1M ago
CDTX
Premium
The Fly
Cidara Therapeutics announces promotion of Davarpanah to CMO
1M ago
CDTX
Premium
The Fly
Elicio Therapeutics appoints Preetam Shah as chief strategy, financial officer
3M ago
CDTX
ELTX
Premium
Ratings
Positive Buy Rating for Cidara Therapeutics Driven by Promising CD388 Development and Safety Profile
3M ago
CDTX
Premium
The Fly
Cidara Therapeutics to present on CD388 at ICAR 2025
3M ago
CDTX
Premium
The Fly
Cidara Therapeutics: CD388 preclinical data published in Nature Microbiology
3M ago
CDTX
Premium
The Fly
Cidara Therapeutics initiated with an Outperform at Citizens JMP
3M ago
CDTX
Premium
Ratings
Buy Rating for Cidara Therapeutics: Promising Potential of CD388 in Influenza Prevention
3M ago
CDTX
Premium
Ratings
Ed Arce’s Buy Rating for Cidara Therapeutics Driven by Accelerated CD388 Program and Promising Phase 2b NAVIGATE Study Developments
3M ago
CDTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
